OTCMKTS:SBMFF - Sino Biopharmaceutical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.05
▼ -0.04 (-3.67%)
1 month | 3 months | 12 months
Get New Sino Biopharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBMFF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBMFF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Sino Biopharmaceutical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.05.

Buy

The current consensus among 2 contributing investment analysts is to buy stock in Sino Biopharmaceutical. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/3/2020Daiwa Capital MarketsInitiated CoverageBuy
i
8/20/2020MacquarieDowngradeOutperform ➝ Neutral
i
5/12/2020Sanford C. BernsteinUpgradeUnderperform ➝ Market Perform
i
3/19/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy
i
4/18/2017Jefferies Financial GroupInitiated CoverageUnderperform
i
(Data available from 6/14/2016 forward)
Sino Biopharmaceutical logo
Sino Biopharmaceutical Limited, an investment holding company, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates in three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Qingkeshu tablets, Qianping injections, Anxian capsules, Yinishu tablets, Genike capsules, Shoufu tablets, Jizhi tablets, and Leweixin injection; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, Sacubatro/Valsartan tablets, Tolvaptan tablets, Rivaroxaban tablets, Edaravone injections, Esmolol Hydrochloride injections, Esmolol Hydrochloride and Sodium Chloride injections, Polidocanol injections, Sacubitril Valsartan Sodium tablets, Urapidil Hydrochloride injections, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules, Taiyan tablets, Zoledronic Acid injections, and Yigu injections. Its principal products also comprise digestive system medicines that consists of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tianjie injections, Fengruineng injections, Tianli injections, and Tianming injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms, and Qingliming injections. In addition, the company engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, it manufactures, sells, and distributes health food; and develops medical technology. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Read More

Today's Range

Now: $1.05
$1.05
$1.07

50 Day Range

MA: $1.06
$1.00
$1.15

52 Week Range

Now: $1.05
$0.84
$1.92

Volume

5,800 shs

Average Volume

5,084 shs

Market Capitalization

$19.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Sino Biopharmaceutical?

The following Wall Street analysts have issued research reports on Sino Biopharmaceutical in the last twelve months: Daiwa Capital Markets, Macquarie, and Zacks Investment Research.
View the latest analyst ratings for SBMFF.

What is the current price target for Sino Biopharmaceutical?

0 Wall Street analysts have set twelve-month price targets for Sino Biopharmaceutical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sino Biopharmaceutical in the next year.
View the latest price targets for SBMFF.

What is the current consensus analyst rating for Sino Biopharmaceutical?

Sino Biopharmaceutical currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SBMFF will outperform the market and that investors should add to their positions of Sino Biopharmaceutical.
View the latest ratings for SBMFF.

What other companies compete with Sino Biopharmaceutical?

How do I contact Sino Biopharmaceutical's investor relations team?

Sino Biopharmaceutical's physical mailing address is Rm 4109 Office Tower Convention Plaza 1 Harbour Road Wanchai, Hong Kong K3, . The company's listed phone number is 852-2802-9886 and its investor relations email address is [email protected] The official website for Sino Biopharmaceutical is www.sinobiopharm.com.